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Different radiolabelling methods alter the pharmacokinetic and biodistribution
properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms
Abstract
Introduction: Tumour-associated urokinase plasminogen activator (uPA) is a critical marker of invasion
and metastasis, and it is recognised as having strong prognostic relevance as well as being a therapeutic
target. The specific uPA inhibitor plasminogen activator inhibitor type-2 (PAI-2, SerpinB2) specifically
targets cell bound uPA and is internalised. Furthermore, preclinical studies have established the “proof-ofprinciple” of uPA-targeting by PAI-2-cytotoxin conjugates in human carcinoma models. However, these
studies also suggest that PAI-2 is rapidly cleared via the renal system with low total dose reaching the
tumour. In this study, a comparative single photon emission computed tomography (SPECT) and
biodistribution (BD) analysis of different forms of PAI-2 labelled with the radioisotopes iodine-123 (123I)
and technetium-99m (99mTc) was undertaken. Methods: The pharmacokinetic (PK) properties and BD of
wild-type, ΔCD-loop and PEGylated ΔCD-loop PAI-2 labelled with the commonly used diagnostic SPECT
radioisotopes 99mTc or 123I were compared in mouse models of human prostate carcinoma. Whole
body SPECT imaging was also performed. Results: Both wild-type or the shorter but active ΔCD-loop form
of PAI-2 123I-labelled indirectly via conjugation to free amine groups (termed 123I-Bn-PAI-2) exhibited low
tumour uptake, rapid excretion and similar PK profiles. Preliminary studies with a short branched-chain
PEGylated 123I-Bn-PAI-2 ΔCD-loop indicated an increase in blood retention time and tumour uptake. All
123I-Bn-labelled radiotracers were largely excreted through the kidneys. By comparison, both wild-type
123I-PAI-2 (labelled directly via tyrosine residues) and 99mTc-PAI-2 displayed different PK/BD patterns
compared to 123IBn- PAI-2, suggesting greater liver based catabolism and thus slower elimination.
SPECT imaging mimicked the BD results of all radiotracers. Conclusion: The different labelling methods
gave distinct PAI-2 BD and tumour uptake profiles, with radioiodination resulting in the best non-tumour
organ clearance profiles. Preliminary analyses with short branched-chain PEGylated 123I-Bn-PAI-2 ΔCDloop suggest that further investigations with other PEGylation reagents are required to optimise this
approach for tumour imaging. These findings impact on the use of PAI-2 for drug delivery and/or
diagnostic development.
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Abstract
Introduction: Tumour-associated urokinase plasminogen activator (uPA) is a cr itical
marker of invasion and metastasis, and it is recognised as having strong prognostic
relevance as well as being a t herapeutic target. The specific uPA inhibitor plasminogen
activator inhibitor type-2 (PAI-2, SerpinB2) specifically targets cell bound uPA and is
internalised. Furthermore, preclinical studies have established the “proof-of-principle” of
uPA-targeting by PAI-2-cytotoxin conjugates in human carcinoma models. However,
these studies also suggest that PAI-2 is rapidly cleared via the renal system with low total
dose reaching the tumour. In this study, a comparative single photon emission computed
tomography (SPECT) and biodistribution (BD) analysis of different forms of PAI-2
labelled with the radioisotopes iodine-123 (123I) and technetium-99m (99mTc) was
undertaken.
Methods: The pharmacokinetic (PK) properties and BD of wild-type, ∆CD-loop and
PEGylated ∆CD-loop PAI-2 labelled with the commonly used diagnostic SPECT
radioisotopes

99m

123

Tc or

I were compared in mouse models of human prostate

carcinoma. Whole body SPECT imaging was also performed.
Results: Both wild-type or the shorter but active ∆CD-loop form of PAI-2
indirectly via conjugation to free amine groups (termed

123

123

I-labelled

I-Bn-PAI-2) exhibited low

tumour uptake, rapid excretion and similar PK profiles. Preliminary studies with a short
branched-chain PEGylated

123

I-Bn-PAI-2 ∆CD-loop indicated an increase in blood

retention time and tumour uptake. All

123

I-Bn-labelled radiotracers were largely excreted

through the kidneys. By comparison, both wild-type
tyrosine residues) and

123

I-PAI-2 (labelled directly via

99m

Tc-PAI-2 displayed different PK/BD patterns compared to 123I-

Bn-PAI-2, suggesting greater liver based catabolism and thus slower elimination. SPECT
imaging mimicked the BD results of all radiotracers.
Conclusion: The different labelling methods gave distinct PAI-2 BD and tumour uptake
profiles, with radioiodination resulting in the best non-tumour organ clearance profiles.
Preliminary analyses with short branched-chain PEGylated

123

I-Bn-PAI-2 ∆CD-loop

suggest that further investigations with other PEGylation reagents are required to
optimise this approach for tumour imaging. These findings impact on t he use of PAI-2
for drug delivery and/or diagnostic development.
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Key Words: Plasminogen activator inhibitor type 2 (PAI-2), serpinB2, small animal
SPECT, pharmacokinetics/biodistribution, iodine-123, technetium-99m.
Abbreviations: BD, biodistribution; ID/g, injected dose per gram; PEG, polyethylene
glycol; PK, pharmacokinetic; PAI-2, plasminogen activator inhibitor type 2; serpin,
serine protease inhibitor; uPA, urokinase plasminogen activator; ∆CD-loop, loop
connecting helices C and D in PAI-2; QTOF-ESI MS, quaternary time of flight
electrospray ionisation mass spectrometry; SPECT, Single Photon Emission Computer
Tomography.
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1. Introduction
With an aging population, the worldwide incidence and mortality of cancer is ever
increasing and many different methods of diagnosis and therapy have been investigated
with varying levels of success [1]. Numerous receptor based targets have been considered
for their potential exploitation as targeting entities for use in nuclear medicine. The
Urokinase Plasminogen Activation (uPA) system is one such physiological process that is
implicated in tumour invasion and metastasis and has the potential for exploitation in this
manner, as over-expression of tumour cell surface uPA has strong prognostic relevance
as well as being a therapeutic target [2, 3]. uPA is synthesised and secreted as a zymogen
whose activation is markedly accelerated upon binding with high affinity to specific cell
surface uPA receptors (uPAR). Active, receptor-bound uPA then efficiently converts any
cell surface-bound zymogen plasminogen into the highly active, serine protease plasmin,
which promotes tissue degradation and remodelling of the local extracellular environment
[4]. The specific uPA inhibitor human plasminogen activator inhibitor type-2 (PAI-2,
serpinB2) efficiently inhibits uPAR-bound uPA resulting in proteolytic inhibition and
rapid and specific receptor-mediated endocytosis of the uPAR/uPA:PAI-2 complex [5-8].
PAI-2 is thus able to efficiently and specifically deliver and concentrate attached
cytotoxins within targeted cells [5, 9]. PAI-2 labeled by chelation with the cytotoxic
alpha-emitting radionuclide Bismuth-213 (213Bi), targets and significantly reduces tumour
growth of human uPA expressing tumours in mouse models [5, 10-12]. Due to the overexpression of uPA in metastatic cells, PAI-2 could possibly be exploited as a highly
specific imaging tool for determining the metastatic potential of tumours.
PAI-2 has high stability in plasma, is non-immunogenic and non-toxic, and has been
successfully radiolabelled with the isotopes

213

Bi [10, 11, 13] and 125I [14] which do not

interfere with the protein’s uPA inhibitory action. Previous biodistribution (BD) studies
in human colorectal tumour-bearing mouse models using human recombinant wild-type
PAI-2 radioiodinated directly with 125I via tyrosine residues, shows rapid clearance from
all organs of the animal, with a small amount of uptake in the tumour (1.3% injected
dose/g) at early time points [14]. Although this excretion profile is ideal for a diagnostic
radiotracer, it is important to increase the tumour uptake of PAI-2 while lowering
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radioactivity retention in all normal organs in order to optimise imaging potential and/or
drug delivery profiles.
Previous studies have shown that the position, type and structure of the radiolabel can
greatly influence the organ and tumour uptake and clearance profiles of proteins and
peptides [15, 16]. Furthermore, the ultimate application will dictate the radiolabelling
approach to use. S PECT is a commonly used imaging modality. The most commonly
used radioisotope for SPECT imaging is

99m

Tc, which has a moderately short half-life of

6.02 h and is generally conjugated to proteins or peptides via metal chelators such as
diethylentriamene pentaacetatic acid (DTPA) or 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴tetraacetic acid (DOTA), or via various amino thiols. Both factors may alter the

pharmacokinetic (PK) and BD properties of the ligand [17]. The SPECT imaging isotope
123

I has a similar energy profile to

99m

Tc but has potential advantages. For example,

123

I

has the highest specific activity available (i.e. has minimal carrier iodine) and can be
easily replaced with 124I for use in PET systems or 131I for therapy. However, radioiodine
attached directly to proteins tends to be unstable in vivo with the radiolabelled protein
being rapidly dehalogenated resulting in thyroid uptake and excretion of free radioiodine
[18]. This can be avoided by indirectly labelling the protein by conjugation of a
radioiodinated prosthetic group to free amines [18]. A comparative assessment of these
different radiolabelling methods on t he PK and BD of PAI-2 has not been previously
undertaken.
An alternative approach to modulating PK and BD profiles of imaging and therapeutic
protein-based radiopharmaceutical agents is to modify the protein. This is very well
exemplified with targeting antibodies and their fragments [19] with small (6.5 kDa)
affibody molecules showing promise for improved imaging of HER-2 positive tumours
[20]. Structurally, wild-type PAI-2 (47 kDa) consists of three β-sheets, 9 α-helices and a
reactive centre loop (that contains the protease recognition site) [21]. PAI-2 also contains
a so-called CD-loop, a sequence of 33 amino acids between the C and D α-helices that
may be involved in various intracellular functions [22], but is not required for uPA
inhibition [23]. Removal of the CD-loop to generate the shortened form of PAI-2 (∆CDloop PAI-2; ~44 KDa) is simpler to express and purify recombinantly, retains full uPA
inhibitory characteristics [23] and may potentially exhibit a more favourable PK profile
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for imaging as is typically seen when the size of a targeting protein is decreased [24]. The
circulation of proteins can also be modified by PEGylation, via conjugation of one or
more polyethylene glycol (PEG) units [25]. Addition of PEG groups to targeting moieties
has the significant effect of increasing the residence time in the blood stream (due to
retardation of renal clearance), hence increasing the bioavailability and clinical potency
of the drug [25, 26]. This approach has also been used to increase tumour uptake while
decreasing kidney uptake of radiolabeled diabodies for improved SPECT imaging
purposes [27].
Evaluation of modified forms of PAI-2 using different radiolabelling techniques via
PK and BD analyses and SPECT imaging, would allow a direct comparison to the known
properties of the PK and BD of wild-type 125I-PAI-2 [14]. The aim of this study was thus
to compare the effect of different

123

I versus

99m

Tc radiolabelling methods with modified

PAI-2 forms on PK and BD profiles, with a further view to optimising tumour uptake of
the radiopharmaceutical for the purpose of tumour imaging and/or radiotherapy.
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2. Materials and Methods
2.1

General

Chemicals and solvents were purchased from Sigma-Aldrich unless otherwise
indicated. All reagents and solvents were of the highest commercially available grade and
used without further purification.
Sydney, Australia, using the

123

I was produced by the National Medical Cyclotron,

124

Xe (p, 2n) reaction and was delivered as

mol/L NaOH at a concentration of 37 GBq/mL.

123

I-NaI in 0.02

99m

Tc obtained from a Gentech®

Molybdenum-[99Mo]/Technetium generator (ANSTO Health, Lucas Heights, Australia).
IsoLinkTM was obtained from Mallinckrodt (Covidien). Zeba desalt spin columns were
purchased from Quantum Scientific. (Methyl-PEO 12 )-PEO 4 -NHS ester (2420.80 Da) was
purchased from Pierce Protein Research Products (Thermo Fisher Scientific, USA).
Human recombinant wild-type (47 kDa) and ∆CD-loop (44 KDa) PAI-2 were provided
by PAI-2 Pty Ltd (Sydney, Australia) or made in-house as described [23].
2.2

Radiolabelling

Radioiodination of both wild-type and ∆CD-loop PAI-2 was performed using direct
and indirect methods. Direct radiolabelling was performed using a modified BoltonHunter method employing Iodogen (10-50 µg) as the oxidant together with the protein (550 µg) in PBS (pH 7.4) and Na123I (40-800 MBq). Unincorporated

123

I was separated

from protein purified using a Zeba desalt spin column as per manufacturer’s instructions.
An incorporation yield of

123

I onto PAI-2 of 15-30% was obtained by this method.

Quality control and radiochemical stability were ascertained on a radio-analytical HPLC
system consisting of a Waters 616 pum p, a Waters 486 U V-vis (UV= 280 nm) with an
inline γ -detector (Ortec) and a B iosep 2000 Phenomenex column (300 x 7.8 mm) or
3000 Phenomenex column (75 x 7.5mm) at 1 ml per min, using a phosphate buffer 100
mM, pH 7.4, NaCl 150 mM mobile phase. The purity and stability of the resultant

123

I-

PAI-2 was found to be greater than 95% at room temperature for a minimum of 2 h as
assessed by radio-analytical HPLC chromatography. The indirect radiolabelling method
was based on a previously described method [28] and involved the conjugation of 123I-Nsuccinimidyl 3-iodobenzoate (prepared from the corresponding stannane) to free amine
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groups of the PAI-2 protein. Briefly, to N-succinimidyl 3-trimethylstannyl benzoate (0.25
mg) in 300 μl of acetic acid/methanol 5/95 was added 770 MBq (80 µL) of Na123I in 0.02
M NaOH and 30 µl of Chloramine-T (1 mg /300 µl of acetic acid/methanol 5/95). After
5 min at room temperature with shaking, the solution was purified by semi-preparative
HPLC as described above (except that a Phenomenex Bondclone C18 column (10 µm,
300 × 7.8 mm) was used) to obtain the

123

I-N-succinimidyl 3-iodobenzoate in 55-70%

incorporation yields. The radiotracer was evaporated to dryness, and then PAI-2 (30 - 60
µg in 200 µL 0.1 M phosphate buffer, pH 8.5) was added to the activity and shaken for
approximately 30 min at room temperature. The mixture was purified using a Zeba desalt
spin column as per manufacturer’s instructions and the resulting 123I-3-iodobenzoyl-PAI2 (123I-Bn-PAI-2) in 20-40% radiochemical yield was formulated in PBS pH 7.4
containing 0.01% Tween 80 for use in biological evaluations. The radiotracer was stable
(greater than 95%) at room temperature for a minimum of 3 h a s measured by radioanalytical HPLC. A representative chromatogram is shown in Supplementary Figure 1.
Radiolabelling of wild-type PAI-2 with 99mTc was performed using PAI-2-DTTA [13]
using a method modified from Vera et al. [29].

99m

Tc 100 – 300 MBq and PAI-2-DTTA

were added together at a ratio of approximately 1 µg protein: 0.55 MBq99mTc in 250 µL
0.9% saline and mixed by bubbling nitrogen through the solution for 10 min. Then 250
µL of 0.5 m M ascorbic acid in 0.9% saline was added followed immediately by the
addition of 25 µL of 1 mM acidified tin chloride solution (made fresh by addition of 75
µL of HCl (37%) to 5 mg of SnCl 2 , followed by 25 µL of 0.9% saline). The reaction was
incubated at room temperature in the dark for 50 min and then centrifuged at 2000 g for
10 min after which time a one-tenth volume of 10 × sterile PBS (pH 7.4) was added. The
mixture was purified using a Zeba desalt spin column as above and the radiotracer
analysed by radio-analytical HPLC also as described above. The percent incorporation
was > 95%.
All radiolabelling procedures were performed at least three times. Protein stability and
inhibitory activity of the radiolabelled PAI-2 species were confirmed by their ability to
form complexes with active uPA as detected by SDS-PAGE and autoradiography as
previously described [12-14] (data not shown).

-8-

2.3

PEGylation of PAI-2

PEGylation of PAI-2 ∆CD-loop was performed by conjugation of the protein with the
branched (methyl-PEO 12 )-PEO 4 -NHS ester as described by the manufacturer and adapted
from Hermanson [30]. Briefly, 25 mM (methyl-PEO 12 )-PEO 4 -NHS ester freshly
dissolved in anhydrous dimethyl formamide was added to 1 mg/mL PAI-2 in phosphate
buffer (pH 8.0) to give > 20-fold molar excess of the PEG reagent to protein. The
reaction mixture was incubated for at least 3 h at 37oC after which the PEGylated protein
was purified away from non-reacted PEGylation reagent using a Zeba desalt spin column
as above. Protein conjugation and inhibitory activity was confirmed as described above.
In general, >80 % of the protein was PEGylated with 1- 4 PEG groups achieved as
determined by SDS-PAGE and QTOF-ESI mass spectrometry (Supplementary Figure 2).
2.4

Cell lines and animals

PC-3 human prostate carcinoma cell lines were cultured in RPMI-1640 supplemented
with 10% FCS at 37ºC under 5% CO2: 95% atmosphere and cell surface expression of
uPAR and uPA was verified by indirect immunofluorescence using dual colour flow
cytometry as previously described [5].
Animal experiments were performed in compliance with the NHMRC Australian
Code of Practice for the care and use of animals for scientific purposes and sanctioned by
the University of Wollongong and ANSTO Animal Care and Ethics Committees. Male
BALB/C nude mice were purchased aged 4-5 weeks old from the Animal Resources
Centre (Canning Vale, WA, Australia). Mice were inoculated subcutaneously in the flank
with 1 × 107 PC-3 human prostate adenocarcinoma cells.

All animals were used

approximately 3 w eeks after inoculation of PC-3 cells at which stage tumours could be
palpated in ~90% of mice. Animals used for experiments carried tumours no greater than
12mm and no less than 5mm in diameter. Tumours were positive for uPA expression as
determined by immunohistopathological methods (Supplementary Figure 3) as previously
described [12].
2.5

SPECT Imaging

To further study the pharmacokinetic profiles and hence determine the tumour
imaging potential of the above radiotracers, SPECT imaging was performed using a high
-9-

resolution γ-camera (X-SPECTTM, Gamma Medica Inc, USA), designed for laboratory
animals. The γ-camera is equipped with an array of discrete 2 × 2 × 6 mm N aI(Tl)
crystals optically isolated from each other and a high resolution parallel hole collimator
with a 12.5 × 12.5 cm field of view. PC-3 tumour bearing mice were anaesthetised via
inhalant isoflurane (ForthaneTM) in 200 m L/min oxygen using a nose cone fitted to the
animal bed and planar imaged at 5-30 min, 1, 3, 6 and 24 h after intravenous injection of
7-10 MBq radiotracer. Animal body temperature was maintained with a warm air blower
during anesthesia. Prior to imaging, the field of view was corrected for uniformity by
filling a Perspex phantom with 80 MBq of 123I or 99mTc and allowing 20,000 counts to be
collected. After the uniformity table was collected and applied, the same phantom was
rescanned collecting 3000 counts for quality control purposes. QC results indicated the
standard deviation in the field of view was < 6% at all times.
2.6

Biodistribution (BD)

To quantitatively evaluate the pharmacokinetic properties of the various PAI-2
radiotracers, BD studies were conducted in PC-3 tumour bearing mice. Animals were
injected with 0.37 – 0.74 MBq of the various radiotracers in 100 µL saline through the
lateral tail vein and sacrificed by cervical fracture under the influence of CO 2 between 5
min and 24 h a fter injection. Blood and selected organs were weighed and their
radioactivity measured with a γ-counter (Wallac 1480). The percent of injected activity in
each organ was calculated by comparison to suitable dilutions of the total dose of the
radiotracer injected. The amount of radioactivity in each organ, expressed in terms of
percent of injected dose (% ID) was found by dividing the % ID for each organ by the
weight of the organ (% ID/g), corrected for the amount of radioactivity remaining in the
tail (always < 9%.). Blood clearance profiles were determined by plotting the percentage
of the injected dose remaining in the blood over time post radiotracer injection and fitted
to a one or two phase exponential decay model using GraphPad Prism version 5.00 for
Windows, (GraphPad Software, San Diego CA USA). All values were corrected for
radioactivity decay and 5 mice were used for each time point.
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2.7

Statistics

Statistical significance of different groups was determined using two-way ANOVA or
paired two-tailed Students T-test (GraphPad Prism V 5.1; San Diego, CA, USA). P
values < 0.05 were considered statistically significant.
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3. Results
3.1

SPECT Imaging Studies

The whole body distribution of wild-type

123

I-PAI-2,

123

I-Bn-PAI-2 and

99m

Tc-PAI-2

in mice bearing human prostate carcinoma was first compared by SPECT imaging over
24 h. Figure 1 shows representative SPECT images acquired at 3 h post radiotracer
injection where obvious differences in radiotracer distribution could be seen between all
3 radiolabelling methods. By 3 h, very little radioactivity remained in the kidneys after
injection of
(Figure 1A).

123

I-Bn-PAI-2 with the majority of radioactivity detected in the bladder

123

I-PAI-2, prepared by the direct radioiodination method, displayed a

different biodistribution pattern to that of 123I-Bn-PAI-2 (Figure 1B) that is suggestive of
radiotracer being also taken-up into the liver-hepatobiliary system. As previously
reported for other proteins radioiodinated directly via their tyrosine residues [18], the
increased radioactivity in the thyroid after injection with123I-PAI-2 (Figure 1B) compared
to 123I-Bn-PAI-2 (Figure 1A), suggests significant dehalogenation of 123I-PAI-2, possibly
via in vivo metabolism of the protein.99mTc-PAI-2 resulted in even greater uptake of
radioactivity into excretory organs (Figure 1C). Renal excretion within the first 40 min
was evident from bladder accumulation of radioactivity following both

123

I-PAI-2 and

99m

Tc-PAI-2 administration. For all radiotracers very little tumour accumulation was

observed.
The imaging patterns of indirectly labelled wild-type PAI-2 (123I-Bn-PAI-2) versus the
∆CD-loop form (123I-Bn-PAI-2 ∆CD-loop) indicated that

123

I-Bn-PAI-2 ∆CD-loop was

perhaps even more rapidly cleared via renal excretion as the only remaining radioactivity
that could be detected by 3 h was in the bladder (Figure 1D). SPECT images of mice
acquired within 5 to 20 min after either radiotracer injection indicated that radioactivity
was rapidly disseminated throughout the body, with accumulation in the bladder evident
within 5 – 10 min, especially for the CD-loop form (data not shown). PEGylated 123I-BnPAI-2 ∆CD-loop followed a similar imaging pattern to non-PEGylated

123

I-Bn-PAI-2

∆CD-loop though the level of circulating radioactivity at 3 h pos t injection (Figure 1E)
appeared to be higher than for the non-PEGylated radiotracer (Figure 1D).
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These observations were confirmed quantitatively as described in the following PK
and BD studies.

3.2

Blood clearance evaluations

As suggested by SPECT imaging, blood levels of radioactivity in mice injected with
123

I-Bn-PAI-2 or 123I-Bn-PAI-2 ∆CD-loop rapidly declined between 5 and 60 min (Figure

2A and B, respectively). This was especially the case for

123

I-Bn-PAI-2 ∆CD-loop, with

radioactivity reaching detection limits 3 h after administration (Figure 2B). There was no
distinction between distribution and elimination phases of the radioactivity as the data
best fit a one-phase decay model for both radiotracers with half lives of approximately 17
and 12 min for the wild-type and ∆CD-loop PAI-2 forms, respectively. These values
corresponded to the SPECT images where radioactivity was rapidly eliminated via the
kidneys with minimal metabolism as evidenced by no accumulation of 123-I in the thyroid
for either

123

I-Bn-PAI-2 or

123

I-Bn-PAI-2 ∆CD-loop. In contrast, directly radioiodinated

wild-type PAI-2 exhibits a biphasic PK profile [14] and was seen by SPECT (refer to
Figure 1B) to reside in the body for longer than the indirectly labelled forms (refer to
Figures 1A and D). However, PEGylated

123

I-Bn-PAI-2 ∆CD-loop also exhibited a

biphasic pharmacokinetic profile consisting of an initial decay phase of rapid
radioactivity distribution (~7 min) followed by a s low decay phase of radioactivity
clearance (~ 111 m in) (Figure 2C). Compared to the non-PEGylated species there was
increased blood retention of radioactivity by 3 h after administration, which was also
somewhat reflected in the blood distribution seen in the SPECT images (refer to Figure
1E).
The

99m

Tc-PAI-2 (wild-type) data best fits a one-phase decay model. Significant

amounts of radioactivity remained in the blood 24 h a fter injection as reflected by a
longer T 1/2 of 90 min (Figure 2D). This also compared well to the SPECT images (refer
to Figure 1C) suggestive of a longer residence time of 99mTc-PAI-2 in mice compared to
any of the radioiodinated protein forms.
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3.3

Biodistribution

The BD patterns of the differently radiolabelled PAI-2 forms in mice bearing prostate
tumours were determined over 24 h. Within the first 30 min after injection of

123

I-Bn-

PAI-2 ∆CD loop, kidneys and livers exhibited the greatest uptake of radioactivity which
quickly declined thereafter (Table 1). This pattern was reflected in the other organs
analysed with any substantial uptake (> 2% ID/g), except for thyroid and tumour
(discussed further below). Whilst a similar metabolic pattern for most organs was seen
after administration of

123

I-Bn-PAI-2, kidney uptake and elimination of radioactivity

levels was slower than for 123I-Bn-PAI-2 ∆CD-loop in the first hour (Table 1). After 1 h,
very little (<6% or < 1% for wild-type versus ∆CD-loop forms, respectively) of the total
injected dose/g of the radioiodinated proteins remained in any organ indicating very fast
elimination, as suggested by the blood clearance patterns, especially for PAI-2 ∆CD-loop.
PEGylation did not substantially alter the BD patterns of

123

I-Bn-PAI-2 ∆CD-loop for

most organs except for the liver and kidneys, where uptake of radioactivity was
significantly lower at 5 – 30 min and 30 min post injection (p < 0.05), respectively,
compared to non-PEGylated 123I-Bn-PAI-2 ∆CD-loop (Table 1). The metabolic pattern of
99m

Tc-PAI-2 differed from all of the radioiodinated forms where substantial uptake of

radioactivity was evident within the first 5 min after injection into all major organs
including heart and lungs, with very slow to no clearance seen after 6 h (Table 1). Indeed,
after 24 h many organs still retained > 4% ID/g.
The thyroid uptake of radioactivity after either

123

I-Bn-PAI-2,

123

I-Bn-PAI-2 ∆CD-

loop or PEGylated 123I-Bn-PAI-2 ∆CD-loop injection was low with minimal difference in
levels over time between radiotracers (Table 1). While

99m

Tc-PAI-2 showed higher

thyroid uptake overall, these values were still relatively low (minimal thyroid uptake seen
in SPECT images shown in Figure 1).
The pattern of tumour uptake of radioactivity was somewhat modulated by the
different radiolabelling methods and modifications to PAI-2 protein (Figure 3). For the
wild-type protein, radioiodination versus radiometal labelling resulted in significantly
different radioactivity uptake levels at all time points (p <0.01) (Figure 3A). A maximum
uptake of 0.85 ± 0.24 % ID/g occurred at 60 min after

123

I-Bn-PAI-2 injection with a

steady decline in radioactivity levels thereafter. In contrast, radioactivity levels peaked at
- 14 -

1.63 ± 0.33 %ID/g at 5 min after 99mTc-PAI-2 injection and were retained at this level for
3 h (Figure 3A) before decreasing substantially (data not shown). A comparison of the
indirectly radioiodinated wild-type versus ∆CD-loop PAI-2 forms found no s ignificant
differences in tumour uptake of radioactivity following injection of either radiotracer at
any time points (Figure 3B). However, in contrast to

123

I-Bn-PAI-2, tumour uptake of

radioactivity peaked at 30 m in (0.88 ± 0.12 %ID/g) post

123

I-Bn-PAI-2 ∆CD-loop

injection (Figure 3B). For both radiotracers, tumour radioactivity levels declined to < 0.2
% ID/g by 3 h after injection (Figure 3B). PEGylated

123

I-Bn-PAI-2 ∆CD-loop resulted

in a maximum uptake of radioactivity at 5 min post injection at a l evel (1.6 ± 0.22%
ID/g) that was significantly greater than that attributable to non-PEGylated 123I-Bn-PAI-2
∆CD-loop at this time point (0.71 ± 0.16% ID/g) (p < 0.001) (Figure 3C). Thereafter, the
levels of radioactivity in tumours after injection of PEGylated
compared to non-PEGylated
from each other (Figure 3C).
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123

123

I-Bn-PAI-2 ∆CD-loop

I-Bn-PAI-2 ∆CD-loop were not significantly different

4. Discussion
The aim of these studies were to perform a comparative SPECT and BD analysis of
radioiodinated versus

99m

Tc-labelled wild-type PAI-2, and radioiodinated wild-type

versus the shortened PAI-2 ∆CD-loop form in order to assess organ distribution and
clearance patterns for potential future development as imaging agents for cancer and for
therapeutic radioisotope delivery. Further to this latter application, PEGylation of PAI-2
∆CD-loop was explored as part of an initial investigation to assess the potential to
increase tumour uptake for radiotherapy. As expected, the different labelling methods
modulated the PK and BD properties of PAI-2 to varying degrees. While no significant
benefit in terms of tumour uptake was obtained through use of the shortened version of
the protein, PAI-2 ∆CD-loop retains full uPA inhibitory activity and is more easily
expressed and purified compared to wild-type PAI-2 [23], thus lending itself to a simpler
manufacturing process. Moreover PAI-2 ∆CD-loop can be modified by PEGylation
whilst retaining its activity and prolonging blood retention and tumour uptake of
radiotracer.
Compared to directly radioiodinated PAI-2 where radioactivity associated with the
thyroid is significant (refer to Figure 1B) due to either dehalogenation and/or metabolism
of the radiotracer (intact radioiodinated species were found in plasma 2 h a fter
administration [14]), the very low

123

I levels associated with the thyroid after

administration of indirectly radioiodinated wild-type or ∆CD-loop PAI-2 suggest that the
radiotracers were not metabolised but rather were cleared via the renal system intact.
Whether this is indeed the case would need to be verified by analyses of plasma and urine
samples however, the single phase blood clearance properties and minimal uptake by
discrete organs other than the kidneys lends favour to this hypothesis. Studies have
shown that

111

In-protein complexes achieved using the chelator DOTA may be more

stable in vivo and result in enhanced tissue accumulation of radioactivity [31]. Indeed this
appeared to be the case when comparing organ BD of wild-type 99mTc-PAI-2 versus 123IBn-PAI-2 (or

123

I-Bn-PAI-2 ∆CD-loop), especially from 30 min onwards after injection.

While tumour uptake of radioactivity was also increased and cleared more slowly by
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using

99m

Tc-PAI-2 compared to the radioiodinated forms, this is potentially at the

detriment of also accumulating radioactivity in non-target organs.
Over the first 3 h i n which radioactivity was detectable in tumours by BD studies,
tumour uptake using all forms of radiolabelled PAI-2 was many times less than that in the
blood on a per gram basis, resulting in no t umour imaging capability. The contrast
required to detect tumour masses via imaging compared to normal tissue requires in the
least that the amount of radiotracer circulating in blood to be lower than that in the
tumour on a percent per gram of tissue basis. However the amount of radiotracer
distributed to other non-tumour tissues other than the liver and kidneys, were
exceptionally low, particularly after 1 h pos t radiotracer injection, suggesting potential
for further optimisation as a tumour imaging agent.
Directly radioidinated wild-type 125I-PAI-2 levels peaked in tumours at 30 - 60 min at
1 – 2 %ID/g [14]. That protein reached the tumours was verified by immunoprecipitation
of PAI-2 in previous studies [14]. A similar temporal profile was observed using either
123

I-Bn-PAI-2 (or

123

I-Bn-PAI-2 ∆CD-loop), however at no t ime point did the tumour

uptake exceed 1% per gram of tissue. Due to low levels of tumour accumulation, use of
radioiodinated PAI-2 as SPECT imaging agents would require further optimisation. A
possible explanation for the low tumour uptake of radiotracers is the very short blood
half-life of the proteins, as described above, that did not allow distribution of radiotracer
to organs and rather were immediately excreted via the kidneys. However, even the small
increase in molecular weight obtained through PEGylation of PAI-2 ∆CD-loop using the
2420.80 Da branched chain PEG, resulted in biphasic blood clearance patterns compared
to the single phase exhibited by the non-PEGylated form (refer to Figure 2), and
somewhat increased both retention of the radiotracer in the blood and tumour uptake.
These promising preliminary PEGylation studies suggest that further refinement in this
area may be obtained to produce better PK properties of the radiotracer for use in
radiotherapy. As the PEGylated PAI-2 ∆CD-loop form used in this study was less than 70
kDa (Supplementary Figure 2), it is still considered small enough to be eliminated via the
renal system [25]. A ttachment of longer chain length PEG groups will increase the
molecular weight of the PEGylated protein complex [25], and hypothetically lead to
longer blood retention thus greater opportunity for PAI-2 to interact with cell surface
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associated uPA. Larger PEGylated PAI-2 species would find further application in
radiotherapy as the modified protein may increase the payload of conjugated therapeutic
radiometals delivered to the tumour whilst decreasing kidney uptake. Success has already
been derived using 213Bi-PAI-2 in targeted alpha particle radiotherapy towards metastatic
cancer [11, 12]. We are currently optimizing methods for site-directed conjugation of
larger PEG groups using different PEGylation techniques, chain lengths and molecular
weights (up to 30 kD a), in order to identify the most advantageous changes in
biopharmacokinetic properties to PAI-2.
The human prostate carcinoma mouse model was selected on the basis that the PC-3
cells were, before implantation, shown to express uPA and the model has been used
successfully previously for tumour efficacy studies investigating

213

Bi-PAI-2 as a

radiopharmaceutical [11]. However, histopathology analysis of the post mortem tumour
tissues from BD studies indicated that the pattern of uPA expression in these tumours was
somewhat heterogeneous and not widespread (Supplementary Figure 3), which would
limit the PAI-2 uptake possibly explaining low tumour radiotracer accumulation. While
haematoxylin and eosin staining of the PC-3 tumours showed no necrosis and evidence of
angiogenesis, better in vivo metastases models in terms of uPA levels should also be
investigated. For example, glioma tumour models have been shown to have high uPAR
expression [32]. Indeed, using uPAR binding synthetic peptides and the 64Cu radiolabel,
Li et al. [32] reported accumulation of up to 8.1 %ID/g of tissue in gliomas at 6 h post
injection based on PET imaging studies. Given the potential for the improved imaging
properties of peptides compared to larger proteins, the use of PAI-2 mimetics that retain
their uPA activity are being investigated. The use of 64Cu, 68Ga or other radioisotopes as
a radiolabel for PAI-2 in PET imaging may also be an avenue for exploration.
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Figure Captions
Figure 1. Static SPECT planar images obtained 3 h pos t injection of 10 MBq of each
radiotracer as indicated in mice bearing human prostate carcinoma xenografts. Each
frame represents an image acquisition time of 5 min. Tumour position is to the right of
the bladder (arrow). The scale indicates the highest value in counts/pixel in the image.

Figure 2. Blood clearance profiles for (A)
∆CD-loop, (C) PEGylated

123

123

I-Bn-PAI-2 (wild-type) (B),

I-Bn-PAI-2 ∆CD-loop, and (D)

123

I-Bn-PAI-2

99m

Tc-PAI-2 (wild-type) in

mice bearing human prostate carcinoma xenografts. The T 1/2 values were calculated
using non-linear regression and best fitted a one-phase (A, B, and D) and two-phase (C)
exponential decay model. Values shown are the means of % ID/g of tissue corrected for
tail vein ± SD (n = 5) (% ID remaining in tail < 10%), from a representative experiment.

Figure 3. A comparison of tumour uptake over time for (A) wild-type 123I-Bn-PAI-2 ()
versus 99mTc-PAI-2 (), (B) wild-type 123I-Bn-PAI-2 () versus 123I-Bn-PAI-2 ∆CD-loop
(), and (C)

123

I-Bn-PAI-2 ∆CD-loop () versus PEGylated

123

I-Bn-PAI-2 ∆CD-loop

() in mice bearing human prostate carcinoma xenografts. Values shown are the means
of % ID/g of tissue corrected for tail vein ± SD (n = 5). All curves were compared using
two-way ANOVA with Bonferroni post-test.
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TABLE 1.
Biodistribution of radioiodinated PAI-2 forms and wild-type 99mTc-PAI-2 in mice bearing PC-3 prostate carcinoma xenografts. Values are expressed as
percent of injected dose per gram (%ID/g) of tissue (mean ± SD).

PAI-2 form

123

I-Bn-PAI-2
(wild-type)*

99m

Tc-PAI-2
(wild-type)

123

I-Bn-PAI-2
∆CD-loop*

123

PEG I-BnPAI-2
∆CD-loop*

Time
(min)

Blood

Liver

Kidney

Spleen

Lungs

Heart

Thyroid

Bone

5

20.39 ± 3.22

9.78 ± 1.23

17.11 ± 3.10

4.69 ± 0.50

8.45 ± 1.98

3.871 ± 0.58

3.35 ± 0.63

1.71 ± 0.21

30

6.13 ± 0.98

4.89 ± 0.47

22.31 ± 2.24

2.68 ± 0.86

3.17 ± 0.69

1.88 ± 0.34

2.85 ± 0.55

1.04 ± 0.27

60

5.05 ± 0.94

3.41 ± 0.71

21.65 ± 3.34

3.00 ± 2.36

3.25 ± 0.39

4.16 ± 5.43

4.18 ± 3.47

1.48 ± 0.68

180

1.25 ± 0.34

1.03 ± 0.33

5.57 ± 0.99

0.59 ± 0.24

0.80 ± 0.22

0.41 ± 0.12

2.73 ± 1.48

0.30 ± 0.08

360

0.44 ± 0.11

0.35 ± 0.18

1.41 ± 0.59

0.55 ± 0.68

0.39 ± 0.04

0.15 ± 0.03

5.86 ± 4.83

0.29 ± 0.23

5
30

13.98 ± 3.22

14.48 ± 0.01

12.51 ± 0.82

10.90 ± 2.11

11.25 ± 0.85

4.80 ± 0.26

5.14 ± 1.03

5.01 ± 0.69

7.80 ± 1.44

10.68 ± 2.11

12.66 ± 1.39

7.88 ± 1.98

6.59 ± 1.09

3.16 ± 0.54

6.24 ± 1.49

6.31 ± 0.68

60

8.61 ± 0.65

13.84 ± 2.19

14.24 ± 1.54

8.92 ± 1.72

6.34 ± 0.61

3.06 ± 0.23

6.62 ± 1.38

7.93 ± 1.34

180

6.55 ± 0.72

13.85 ± 2.52

13.70 ± 1.61

7.91 ± 1.24

4.68 ± 0.38

2.17 ± 0.31

11.60 ± 9.62

7.91 ± 1.26

360

4.49 ± 0.44

11.05 ± 1.69

9.44 ± 0.55

6.37 ± 1.96

3.51 ± 0.49

1.43 ± 0.27

6.27 ± 2.00

7.20 ± 0.89

1440

2.30 ± 0.29

5.25 ± 0.32

4.56 ± 0.29

4.92 ± 0.76

1.76 ± 0.38

0.76 ± 0.07

4.04 ± 1.12

7.01 ± 0.83

5

17.28 ± 1.48

15.49 ± 2.53

33.38 ± 2.46

5.35 ± 0.39

8.52 ± 1.16

3.32 ± 0.21

2.87 ± 0.90

1.72 ± 0.28

30

4.06 ± 0.45

8.96 ± 1.08

34.61 ± 5.39

4.23 ± 0.71

4.05 ± 0.71

1.54 ± 0.21

3.02 ± 1.51

1.16 ± 0.17

60

1.00 ± 0.15

2.33 ± 0.31

7.72 ± 1.20

1.67 ± 0.27

1.66 ± 0.35

0.41 ± 0.07

1.11 ± 0.60

0.50 ± 0.09

180

0.17 ± 0.05

0.46 ± 0.05

0.69 ± 0.20

0.60 ± 0.12

0.45 ± 0.15

0.08 ± 0.06

2.86 ± 0.38

0.11 ± 0.03

360

0.16 ± 0.01

0.41 ± 0.11

0.74 ± 0.17

0.43 ± 0.23

0.22 ± 0.08

0.07 ± 0.01

5.70 ± 2.03

0.1 ± 0.03

5

15.99 ± 1.61

7.7 ± 1.09

32.01 ± 8.98

3.53 ± 0.35

7.14 ± 1.11

3.88 ± 1.09

4.76 ± 1.47

2.00 ± 0.59

30

5.67 ± 0.55

3.33 ± 0.53

11.93 ± 1.15

1.98 ± 0.12

3.58 ± 0.54

1.87 ± 0.36

6.20 ± 2.03

2.11 ± 1.53

60

4.51 ± 0.25

1.95 ± 0.16

8.47 ± 0.83

1.48 ± 0.08

2.51 ± 0.34

1.47 ± 0.16

4.79 ± 1.48

0.74 ± 0.17

180

1.81 ± 0.14

0.76 ± 0.08

2.32 ± 0.43

0.68 ± 0.05

1.32 ± 0.41

0.58 ± 0.08

0.58 ± 0.08

0.31 ± 0.03

360

1.25 ± 0.30

0.50 ± 0.22

1.28 ± 0.54

0.94 ± 1.02

0.77 ± 0.27

0.41 ± 0.14

0.41 ± 0.14

0.21 ± 0.09

Data are corrected for tail vein (% ID remaining in tail < 10%), n = 5.
Muscle contained <1.5% per gram and brain contained <0.6% per gram at all time points for all radiotracers
* Data not shown for 1440 min (24 h) as all values <0.12% except for thyroid.
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Representative HPLC analysis of

123

I-Bn-PAI-2. A sample of purified radioiodinated protein

in PBS/0.01% Tween 80 (pH 7.4 ) that had been stored at room temperature for 3 h was
injected onto a Phenomenex Biosep 3000 column 75 x 7.5 mm and separated at a flow rate of
1.0 ml/min. Relative retention times and purity were calculated from Area Under the Curve
using Empower Pro V2 (Waters) software. The major protein peak at 2.55 min in the UV-vis
trace (top panel) corresponds to the radioactivity peak in the gamma detector trace (bottom
panel) indicating that the majority of protein (>95%) was radiolabelled and minimal free 123I or
radiolabelled impurities remained.

SUPPLEMENTARY FIGURE 2

A positive ion QTOF ESI-MS of PEGylated PAI-2 ∆CD-loop in 10 mM ammonium acetate (pH 6.8)
containing 0.1% formic acid. The m/z spectrum shows a Gaussian-type distribution of multiply charged
ions ranging from m/z 1900 – 3300. The difference in mass for each PEGylated PAI-2 species (left hand
side, A - C) represents the weight of PAI-2 plus branched chain PEG ((methyl-PEO 12 )-PEO 4 , 2305.71
Da). A = m ass of PAI-2 (44496.72 Da 1) + 3 (methyl-PEO 12 )-PEO 4 molecules, B = mass of PAI-2 + 2
(methyl-PEO 12 )-PEO 4 molecules, C = m ass of PAI-2 + 1 (methyl-PEO 12 )-PEO 4 molecule. Mass was
calculated using MassLynx MS software (Waters). Inset: SDS PAGE of various PEGylated and nonPEGylated PAI-2 ∆CD-loop samples showing the ability of unmodified and modified PAI-2 to form stable
complexes with uPA. Briefly, PAI-2 ∆CD-loop (lane 1) and PAI-2 ∆CD-loop incubated with 20-fold
molar excess (methyl-PEO 12 )-PEO 4 NHS ester (lane 2) or 50-fold molar excess (methyl-PEO 12 )PEO 4 NHS ester (lane 3) were incubated with uPA (2:1) at 37°C for 30 m in. Samples were then
fractionated under non-reducing conditions using 10% acrylamide SDS PAGE and visualized by staining
with Coomassie blue. Both unmodified PAI-2 ∆CD-loop (lane 4) and PEGylated PAI-2 ∆CD-loop (lane 5
and 6) formed high molecular weight covalent complexes with uPA. Lane 7: uPA.

1

Cochran, B. J.; Gunawardhana, L. P.; Vine, K. L.; Lee, J. A.; Lobov, S.; Ranson, M. The CD-loop of PAI-2 (SERPINB2) is
redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol , 2009, 9, 43.

1

SUPPLEMENTARY FIGURE 3
A.

B.

Representative analysis of uPA expression in PC-3 tumour xenografts excised after BD studies by
immunohistochemical (A) and immunofluoresence (B) staining of formalin-fixed paraffin embedded
sections, performed essentially as previously described. Tissue sections were counterstained with either
(A) Mayer’s hematoxylin or (B) propidium iodide. Positive uPA staining in (A) is indicated by brown
regions and in (B) by green fluorescence (orange regions indicate DNA counterstaining). Insets: Negative
controls.

